Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.59 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320624 | 0.88 | GAA (0.53) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL2624596 | 0.79 | LMNA (0.75) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL4322323 | 0.78 | HCRTR1 (0.67) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL2624459 | 0.78 | HCRTR1 (0.72) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL4310762 | 0.77 | HCRTR1 (0.72) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL4325596 | 0.77 | HCRTR1 (0.71) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL14484106 | 0.76 | LMNA (0.69) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL4312769 | 0.75 | HCRTR1 (0.68) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL1672524 | 0.75 | HCRTR1 (1.00) | HCRTR1HCRTR2LMNATSHRGAA | |
| SCHEMBL4313174 | 0.74 | HCRTR1 (0.52) | HCRTR1HCRTR2LMNATSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001485-B1 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | claimed |
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-05-14 | — | — | US | claimed |
| EP-2001485-B1 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2001485-B1 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-05-14 | — | — | US | disclosed |
| WO-2007126935-A2 | DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124603-A1 | Diazepan Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885LMNA 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.